Stock Scorecard
Stock Summary for Alnylam Pharmaceuticals Inc (ALNY) - $334.50 as of 2/27/2026 5:53:41 PM EST
Total Score
10 out of 30
Safety Score
55 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ALNY
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ALNY
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ALNY
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ALNY
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for ALNY (55 out of 100)
| Stock Price Rating (Max of 10) | 10 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 4 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 5 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 3 |
| Trading Volume (Max of 10) | 8 |
| Price to Earnings (Max of 10) | 1 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for ALNY
Financial Details for ALNY
Company Overview |
|
|---|---|
| Ticker | ALNY |
| Company Name | Alnylam Pharmaceuticals Inc |
| Country | USA |
| Description | Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 12/31/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 334.50 |
| Price 4 Years Ago | 237.65 |
| Last Day Price Updated | 2/27/2026 5:53:41 PM EST |
| Last Day Volume | 880,311 |
| Average Daily Volume | 1,478,775 |
| 52-Week High | 495.55 |
| 52-Week Low | 205.87 |
| Last Price to 52 Week Low | 62.48% |
Valuation Measures |
|
| Trailing PE | 142.78 |
| Industry PE | 26.08 |
| Sector PE | 46.86 |
| 5-Year Average PE | -42.27 |
| Free Cash Flow Ratio | 26.76 |
| Industry Free Cash Flow Ratio | 12.68 |
| Sector Free Cash Flow Ratio | 25.71 |
| Current Ratio Most Recent Quarter | 2.76 |
| Total Cash Per Share | 12.50 |
| Book Value Per Share Most Recent Quarter | 5.96 |
| Price to Book Ratio | 241.13 |
| Industry Price to Book Ratio | 50.08 |
| Sector Price to Book Ratio | 52.77 |
| Price to Sales Ratio Twelve Trailing Months | 11.83 |
| Industry Price to Sales Ratio Twelve Trailing Months | 38.92 |
| Sector Price to Sales Ratio Twelve Trailing Months | 22.39 |
| Analyst Buy Ratings | 14 |
| Analyst Strong Buy Ratings | 6 |
Share Statistics |
|
| Total Shares Outstanding | 132,623,000 |
| Market Capitalization | 44,362,393,500 |
| Institutional Ownership | 101.82% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 2.52% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 212.79% |
| Reported EPS 12 Trailing Months | 2.32 |
| Reported EPS Past Year | 3.63 |
| Reported EPS Prior Year | -1.09 |
| Net Income Twelve Trailing Months | 313,747,000 |
| Net Income Past Year | 313,747,000 |
| Net Income Prior Year | -278,157,000 |
| Quarterly Revenue Growth YOY | 84.90% |
| 5-Year Revenue Growth | 49.77% |
| Operating Margin Twelve Trailing Months | 12.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 1,657,250,000 |
| Total Cash Past Year | 1,657,250,000 |
| Total Cash Prior Year | 966,428,000 |
| Net Cash Position Most Recent Quarter | 649,466,000 |
| Net Cash Position Past Year | 649,466,000 |
| Long Term Debt Past Year | 1,007,784,000 |
| Long Term Debt Prior Year | 1,024,621,000 |
| Total Debt Most Recent Quarter | 1,007,784,000 |
| Equity to Debt Ratio Past Year | 0.44 |
| Equity to Debt Ratio Most Recent Quarter | 0.44 |
| Total Stockholder Equity Past Year | 789,176,000 |
| Total Stockholder Equity Prior Year | 67,088,000 |
| Total Stockholder Equity Most Recent Quarter | 789,176,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 465,383,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 3.51 |
| Free Cash Flow Past Year | 465,383,000 |
| Free Cash Flow Prior Year | -42,589,000 |
Options |
|
| Put/Call Ratio | 0.04 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -10.33 |
| MACD Signal | -13.46 |
| 20-Day Bollinger Lower Band | 296.16 |
| 20-Day Bollinger Middle Band | 400.04 |
| 20-Day Bollinger Upper Band | 503.93 |
| Beta | 0.35 |
| RSI | 42.41 |
| 50-Day SMA | 364.97 |
| 150-Day SMA | 259.33 |
| 200-Day SMA | 242.40 |
System |
|
| Modified | 2/27/2026 5:00:20 PM EST |